Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from June 12, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 10, 2026 — +1.7% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$41.44 – $43.14Entry zone — fair-value band

$43.27Published — price the day we called it

$48.28Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$44.01Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 19 days.

At window close

+1.7%

realized, from the publication price to the last close inside the window

Peak gain

+18.9%

peak, from the publication price — not a realized return

S&P 500, same window

+2.4%

SPY over the identical days, dividend-adjusted

Window close

$44.01

last close inside the window, ended September 10, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published June 12, 2026

Predicted growth

+13%

over the measurement window

Target price

$48.28

the price the thesis aimed for

Entry zone

$41.44 – $43.14

the fair-value band we waited for

Price at publication

$43.27

published June 12, 2026

Confidence

79%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk combines steady demand for health-care medicines with a new boost from approval of an oral obesity drug. Early prescription data suggests the obesity business can grow, though later decisions by employers could make sentiment tougher. The stock looks reasonably valued for its quality, but recent strong buying makes near-term entry less forgiving.

Primary drivers

Approval of an oral obesity drug meaningfully expands treatment options and market reach
Early prescription uptake gives clearer visibility into near-term sales strength
Stable demand for chronic-care medicines helps performance when markets wobble
Relatively low valuation versus quality provides some downside protection

How it played out

NVO: target reached in 19 days

Lyra published NVO at 43.27, with 13% expected growth over the short-term window. The thesis pointed to approval of an oral obesity drug, early prescription uptake, steady demand for chronic-care medicines, and a relatively low valuation as support for the move.

NVO reached the 48.28 target in 19 days. It later peaked at 51.46 on July 29, 2026, for an 18.9% gain. By September 10, 2026, it had fallen back to 44.01, but the target had already been reached inside the window. The thesis played out.

What happened during the window

On July 15, 2026, Novo Nordisk announced European Commission approval of the Wegovy pill for adults with obesity or overweight. On August 4, 2026, the company reported its second-quarter results and raised its 2026 outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals